| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| rs-130830 | matrix metalloproteinase-1 | NA | Successful target | TTD | Hepatitis C[MeSHID:D006526] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | discontinued in phase 2 | unknown |
| rs-130830 | matrix metalloproteinase-13 | NA | Clinical trial target | TTD | Hepatitis C[MeSHID:D006526] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | discontinued in phase 2 | unknown |
| rs-130830 | matrix metalloproteinase-2 | NA | Successful target | TTD | Hepatitis C[MeSHID:D006526] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | discontinued in phase 2 | unknown |
| rs-130830 | matrix metalloproteinase-3 | NA | Patented-recorded target | TTD | Hepatitis C[MeSHID:D006526] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | discontinued in phase 2 | unknown |
| rs-130830 | matrix metalloproteinase-9 | NA | Clinical trial target | TTD | Hepatitis C[MeSHID:D006526] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | discontinued in phase 2 | unknown |
| click here to return to the previous page | ||||||||